Leucine-tRNA ligase · SINGLE PROTEIN · Trichophyton rubrum (strain ATCC MYA-4607 / CBS 118892) (Athlete'sfoot fungus)
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Leucine-tRNA ligase shows approved-linked disease relevance led by tinea. 1 more disease program remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt F2SF18. Start with tinea, then reuse UniProt F2SF18 as the stable protein anchor across project notes and exports.
Start with tinea, then reuse UniProt F2SF18 as the stable protein anchor across project notes and exports.
Leucine-tRNA ligase shows approved-linked disease relevance led by tinea. 1 more disease program remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with tinea because it currently carries approved-linked support. Linked drugs include TAVABOROLE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyleucine--tRNA ligase
Review this target as Leucine-tRNA ligase, mapped to UniProt F2SF18. ChEMBL maps the protein component as leucine--tRNA ligase. Sequence length is 1066 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Leucine-tRNA ligase as ChEMBL target CHEMBL3307222, mapped to UniProt F2SF18. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Leucine-tRNA ligase is the right protein anchor across sources, using UniProt F2SF18 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why tinea is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Leucine-tRNA ligase |
| Target Type | SINGLE PROTEIN |
| Organism | Trichophyton rubrum (strain ATCC MYA-4607 / CBS 118892) (Athlete'sfoot fungus) |
| UniProt | F2SF18 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | leucine--tRNA ligase |
| UniProt Accession | F2SF18 |
| Component Type | Protein |
| Sequence Length | 1066 aa |
leucine--tRNA ligase
Review this target as Leucine-tRNA ligase, mapped to UniProt F2SF18. ChEMBL maps the protein component as leucine--tRNA ligase. Sequence length is 1066 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Leucine-tRNA ligase shows approved-linked disease relevance led by tinea. 1 more disease program remain visible in the same review block.
Start review with tinea because it currently carries approved-linked support. Linked drugs include TAVABOROLE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.